WallStreetZenWallStreetZen

NASDAQ: ARQT
Arcutis Biotherapeutics Inc Stock

$9.12-0.12 (-1.3%)
Updated May 16, 2024
ARQT Price
$9.12
Fair Value Price
-$1.72
Market Cap
$1.06B
52 Week Low
$1.76
52 Week High
$13.17
P/E
-3.26x
P/B
4.69x
P/S
10.34x
PEG
N/A
Dividend Yield
N/A
Revenue
$106.39M
Earnings
-$217.42M
Gross Margin
93%
Operating Margin
-172.85%
Profit Margin
-204.4%
Debt to Equity
1.13
Operating Cash Flow
-$198M
Beta
0.95
Next Earnings
Jun 14, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ARQT Overview

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ARQT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ARQT ($9.12) is overvalued by 631.32% relative to our estimate of its Fair Value price of -$1.72 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ARQT ($9.12) is not significantly undervalued (631.32%) relative to our estimate of its Fair Value price of -$1.72 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ARQT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ARQT due diligence checks available for Premium users.

Be the first to know about important ARQT news, forecast changes, insider trades & much more!

ARQT News

Valuation

ARQT fair value

Fair Value of ARQT stock based on Discounted Cash Flow (DCF)
Price
$9.12
Fair Value
-$1.72
Undervalued by
631.32%
ARQT ($9.12) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ARQT ($9.12) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ARQT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ARQT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-3.26x
Industry
8.43x
Market
31.03x

ARQT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
4.69x
Industry
6.06x
ARQT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ARQT's financial health

Profit margin

Revenue
$49.6M
Net Income
-$35.4M
Profit Margin
-71.4%
ARQT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ARQT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$478.5M
Liabilities
$253.6M
Debt to equity
1.13
ARQT's short-term assets ($468.06M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARQT's short-term assets ($468.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARQT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$31.6M
Investing
-$28.7M
Financing
$161.8M
ARQT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ARQT vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ARQT$1.06B-1.30%-3.26x4.69x
SAVA$1.03B-6.30%-18.59x13.16x
AUTL$1.08B+3.56%-3.39x9.71x
VRNA$1.08B-4.23%-16.70x4.81x
CNTA$1.01B+1.82%-6.35x4.70x

Arcutis Biotherapeutics Stock FAQ

What is Arcutis Biotherapeutics's quote symbol?

(NASDAQ: ARQT) Arcutis Biotherapeutics trades on the NASDAQ under the ticker symbol ARQT. Arcutis Biotherapeutics stock quotes can also be displayed as NASDAQ: ARQT.

If you're new to stock investing, here's how to buy Arcutis Biotherapeutics stock.

What is the 52 week high and low for Arcutis Biotherapeutics (NASDAQ: ARQT)?

(NASDAQ: ARQT) Arcutis Biotherapeutics's 52-week high was $13.17, and its 52-week low was $1.76. It is currently -30.75% from its 52-week high and 418.18% from its 52-week low.

How much is Arcutis Biotherapeutics stock worth today?

(NASDAQ: ARQT) Arcutis Biotherapeutics currently has 115,764,164 outstanding shares. With Arcutis Biotherapeutics stock trading at $9.12 per share, the total value of Arcutis Biotherapeutics stock (market capitalization) is $1.06B.

Arcutis Biotherapeutics stock was originally listed at a price of $21.80 in Jan 31, 2020. If you had invested in Arcutis Biotherapeutics stock at $21.80, your return over the last 4 years would have been -58.17%, for an annualized return of -19.58% (not including any dividends or dividend reinvestments).

How much is Arcutis Biotherapeutics's stock price per share?

(NASDAQ: ARQT) Arcutis Biotherapeutics stock price per share is $9.12 today (as of May 16, 2024).

What is Arcutis Biotherapeutics's Market Cap?

(NASDAQ: ARQT) Arcutis Biotherapeutics's market cap is $1.06B, as of May 18, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Arcutis Biotherapeutics's market cap is calculated by multiplying ARQT's current stock price of $9.12 by ARQT's total outstanding shares of 115,764,164.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.